Celgene $9 billion acquisition of Juno Therapeutics

22/1/2018
Public acquisition

$ 9 billion

Announced

22/1/2018


Overview:

  • Biotechnology company Celgene has acquired Juno Therapeutics in a $9 billion deal. 
  • Celgene previously held 9.7% of Juno. 
  • Juno develops cancer immunotherapy drugs. 
  • JP Morgan Securities acted as financial adviser for Celgene and Morgan Stanley advised Juno. 
  • The deal comes on the same day as Sanofi's $11.6 billion acquisition of Bioverativ. 

Kurt Stumpo - Journalist

Continue reading...

New to IFLR1000?

Register today for FREE:

  • Understand market dynamics, with data broken by deal type and more
  • Access law firms and lawyers involved in deals
  • Gain unique insight into lawyers recent work
REGISTER NOW

Sign in